Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma

Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma

Authors

  • NICOLA SGHERZA a:1:{s:5:"en_US";s:147:"Hematology and Bone Marrow Transplantation Unit - AOUC Policlinico, Department of Emergency and Organ Transplantation, "Aldo Moro" University, Bari";}
  • PAOLA CURCI Hematology and Bone Marrow Transplantation Unit - AOUC Policlinico, Department of Emergency and Organ Transplantation, "Aldo Moro" University, 70124, Bari, Italy
  • VANDA STRAFELLA Hematology and Bone Marrow Transplantation Unit - AOUC Policlinico, Department of Emergency and Organ Transplantation, "Aldo Moro" University, 70124, Bari, Italy
  • RITA RIZZI Hematology and Bone Marrow Transplantation Unit - AOUC Policlinico, Department of Emergency and Organ Transplantation, "Aldo Moro" University, 70124, Bari, Italy
  • PELLEGRINO MUSTO Hematology and Bone Marrow Transplantation Unit - AOUC Policlinico, Department of Emergency and Organ Transplantation, "Aldo Moro" University, 70124, Bari, Italy

Keywords:

multiple myeloma, COVID-19, IL-6, tocilizumab, siltuximab, sarilumab

References

1. Liang W, Guan W, Chen R, Wang W, Li J, Xu K, Li C, Ai Q, Lu W, Liang H, Li S, He J. Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China. Lancet Oncol. 2020 Mar;21(3):335-337. doi: 10.1016/S1470-2045(20)30096-6. Epub 2020 Feb 14. PMID: 32066541; PMCID: PMC7159000

2. Crisafulli S, Isgrò V, La Corte L, Atzeni F, Trifirò G. Potential Role of Anti-interleukin (IL)-6 Drugs in the Treatment of COVID-19: Rationale, Clinical Evidence and Risks. BioDrugs. 2020 Aug;34(4):415-422. doi: 10.1007/s40259-020-00430-1. PMID: 32557214; PMCID: PMC7299248

3. Atal S, Fatima Z. IL-6 Inhibitors in the Treatment of Serious COVID-19: A Promising Therapy? Pharmaceut Med. 2020 Aug;34(4):223-231. doi: 10.1007/s40290-020-00342-z. PMID: 32535732; PMCID: PMC7292936.
4. Zhang S, Li L, Shen A, Chen Y, Qi Z. Rational Use of Tocilizumab in the Treatment of Novel Coronavirus Pneumonia. Clin Drug Investig. 2020 Jun;40(6):511-518. doi: 10.1007/s40261-020-00917-3. PMID: 32337664; PMCID: PMC7183818.


5. Hirata T, Shimazaki C, Sumikuma T, Ashihara E, Goto H, Inaba T, Koishihara Y, Nakagawa M. Humanized anti-interleukin-6 receptor monoclonal antibody induced apoptosis of fresh and cloned human myeloma cells in vitro. Leuk Res. 2003 Apr;27(4):343-9. doi: 10.1016/s0145-2126(02)00179-0. PMID: 12531226.

6. Matsuyama Y, Nagashima T, Honne K, Kamata Y, Iwamoto M, Okazaki H, Sato K, Ozawa K, Minota S. Successful treatment of a patient with rheumatoid arthritis and IgA-κ multiple myeloma with tocilizumab. Intern Med. 2011;50(6):639-42. doi: 10.2169/internalmedicine.50.4636. Epub 2011 Mar 15. PMID: 21422694.

Downloads

Published

12-05-2021

Issue

Section

CORRESPONDENCE - SPECIAL COVID19

How to Cite

1.
SGHERZA N, CURCI P, STRAFELLA V, RIZZI R, MUSTO P. Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma. Acta Biomed [Internet]. 2021 May 12 [cited 2024 Aug. 17];92(2):e2021205. Available from: https://mattioli1885journals.com/index.php/actabiomedica/article/view/11395